Karidine

Quick links to important sections

Karidine

Method of action: Analgesic, Analgetic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karidine

Property Description
Active Ingredient Phenazopyridine Hydrochloride (Phenazopyridine HCl)
Form Oral Tablet or Film-Coated Tablet
Pharmacological Class Urinary Tract Analgesic
General Purpose Symptomatic relief of pain and irritation in the urinary tract
Origin Synthetic Azo Dye Derivative

Karidine: Definition and Pharmacological Classification

Karidine is the trade name for a medicinal product whose active component is Phenazopyridine Hydrochloride (HCl), which is officially categorized as a highly specific Urinary Tract Analgesic. This classification indicates the substance is utilized solely for its targeted pain-relieving effects within the lower urinary system, differentiating its function from systemic antibiotics or general pain medications. The core of Karidine is a synthetic compound derived from an azo dye. As a single-ingredient product, its role is purely for the symptomatic relief of discomfort and is not formulated to eliminate underlying conditions, such as bacterial infection.

Composition, Form, and General Purpose

Phenazopyridine is manufactured for oral administration, typically formulated as a solid preparation, such as a tablet or film-coated tablet. This dosage form is designed to ensure the active ingredient is absorbed and subsequently concentrated within the urine. Karidine is commonly available in the market as an Over-The-Counter (OTC) preparation in lower concentrations, offering accessibility for rapid relief.

This process enables the drug to deliver its therapeutic benefit by exerting a local analgesic effect through direct contact with the irritated tissues of the urinary tract mucosa. The primary general purpose of Karidine is to achieve prompt symptomatic relief from common urinary discomforts, including the burning sensation (dysuria) and pain. The synthetic azo dye structure is responsible for the expected red-orange discoloration of the urine observed during its use.

Regulatory References

  1. MedlinePlus

What side effects are possible with Karidine?

Official Safety Profile

The official safety information for Karidine (Phenazopyridine Hydrochloride) details potential adverse reactions across several physiological systems. Common effects documented in regulatory labeling include gastrointestinal disturbances (such as nausea and vomiting), neurological effects (such as headache and vertigo), and dermatological reactions (rash and itching or pruritus).

An expected, non-pathological safety characteristic is the intrinsic reddish-orange discoloration of the urine, which is a direct consequence of the drug's properties as an azo dye.

Serious Adverse Reactions and Systemic Risk

Official documents list several serious adverse reactions, often associated with use at overdosage levels or in susceptible patients. These include severe hematologic effects such as Methemoglobinemia and Hemolytic Anemia, as well as toxicity affecting major organs, including Hepatic Toxicity and Acute Renal Toxicity [NIH]. The potential for these serious reactions underscores the drug's safety profile.

Population-Specific Constraints

Regulatory labeling establishes key limitations based on pre-existing health conditions. Karidine is officially contraindicated for use in individuals with pre-existing renal insufficiency or severe liver disease [Health Canada]. Impaired function in these organs can lead to drug accumulation and an increased risk of systemic toxicity. Caution is also advised for older adults and patients with certain hereditary conditions, such as G-6-PD deficiency.

Time-Related Safety Indicators

A specific safety pattern noted in regulatory documentation relates to drug accumulation. The development of a yellowish tinge of the skin or the whites of the eyes (sclerae) serves as an official indicator of drug buildup, which may occur after prolonged use (e.g., more than two days) or due to underlying renal impairment. The drug also has the potential to interfere with certain clinical laboratory tests that rely on colorimetric analysis.

Overdose and Emergency Response

Overdose with Karidine (Phenazopyridine HCl) is primarily documented by regulatory authorities as a risk for severe systemic and hematologic toxicity. A massive, acute overdose is generally associated with the development of methemoglobinemia, which severely limits the blood's oxygen-carrying capacity. This can lead to serious outcomes, including oxidative hemolytic anemia, as well as potential acute renal and hepatic failure. Regulators note that methemoglobinemia, if untreated, can result in collapse and death.

Documented Signs and Required Actions Manifestation/Risk Required Action (as labeled)
Cyanosis (blue skin discoloration), headache, confusion, fatigue Seek immediate medical attention or contact a Poison Control center for suspected acute overdose.
Jaundice (yellowing of skin or eyes), little or no urination Discontinue the drug immediately if observed, as this may indicate drug accumulation due to impaired renal function.

Treatment, as described in regulatory labeling, involves symptomatic and supportive treatment. For methemoglobinemia, specific antidotal agents such as Methylene Blue or Ascorbic Acid are documented procedures. Elderly patients are noted to have an increased risk of drug accumulation and toxicity due to typically declining renal function, and patients with G-6-PD deficiency are predisposed to oxidative hemolysis, which requires specific consideration during overdose management.

Therapeutic Uses of Karidine

What Karidine Treats: Main Uses and Benefits

Karidine is commonly used to help with the symptomatic relief of pain, burning, urgency, and increased frequency. The medicine is applied across domains where additional symptomatic support is needed, and is commonly used to help with acute and disruptive episodes of urinary discomfort. It helps address symptom clusters that may become intense or disruptive.

Symptom Management and Clinical Contexts

Karidine is relevant in conditions characterized by periods of heightened symptoms, such as an acute Urinary Tract Infection (UTI). It is often used when symptoms intensify and supportive relief is needed alongside primary treatment. It is also applied in situations involving discomfort following trauma, surgery, or endoscopic procedures like cystoscopy, assisting with maintaining functional stability and helping improve day-to-day comfort during symptomatic periods.


Quick Fact: Supportive Management of Acute Urinary Discomfort

Karidine provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. DailyMed Labeling, NIH

Eligibility and Restrictions for Use

Karidine (Phenazopyridine HCl) eligibility is strictly defined by regulatory documents based on organ function, age, and pre-existing conditions.

Populations Who Must Not Use Karidine (Contraindications)

Karidine is contraindicated and must not be used in the following patient groups, as it may lead to drug accumulation and potential toxicity:

  • Patients with Renal Insufficiency or Kidney Disease (including glomerulonephritis or uremia).
  • Patients with Severe Liver Disease.
  • Individuals with known hypersensitivity to Phenazopyridine HCl or any component of the formulation.

Restricted and Conditional Use

Population Group Regulatory Status Constraint Basis
Pediatric Patients Use Not Established Safety and effectiveness are not established for children under 12 years of age.
Older Adults Use with Caution Caution is required due to the higher likelihood of reduced renal function.
G6PD Deficiency Use with Caution Advised due to increased susceptibility to certain blood disorders.
Pregnancy Conditional Use Use is permitted only if clearly needed (classified as Pregnancy Category B).
Lactation Avoided/Caution Generally avoided or used with caution, as excretion into breast milk is not established.

What should I know about interactions with other medicines?

The regulatory documentation for Karidine (Phenazopyridine Hydrochloride) outlines its interaction profile across pharmacokinetic, timing, and procedural constraints, rather than listing numerous enzyme-mediated drug-drug combinations.

Interaction Profile: Official Regulatory Findings

Feature Official Regulatory Information
Exposure-Altering Interaction Co-administration with the antibacterial combination Trimethoprim/Sulfamethoxazole may result in increased plasma concentrations of Phenazopyridine HCl and both antibacterial components, establishing a specific pharmacokinetic change.
Timing Restriction When administered concurrently with any antibacterial agent for the treatment of a urinary tract infection, the duration of Karidine use must not exceed 2 days.
Population Note The official prescribing information notes that individuals with impaired renal excretion are at a heightened risk of drug accumulation due to the potential for reduced clearance.

Substance and Procedural Constraints

Official labeling specifies that Karidine, due to its properties as an azo dye, interferes with numerous laboratory tests. Specifically, the substance can affect the accuracy of urinalysis results based on colorimetric, photometric, or fluorometric analysis for substances like urine ketone, glucose, bilirubin, and albumin. Furthermore, to optimize administration conditions and reduce gastric upset, the product is advised to be taken with or following food or a snack.

Connection to the overall interaction profile: The regulatory interaction structure is defined primarily by a mandatory time limit for co-administration with antibiotics and documented interference with diagnostic procedures. This profile addresses specific pharmacokinetic changes and clearance concerns rather than comprehensive metabolic pathway interactions.

Mechanism of Action

How Karidine Works: Molecular Mechanism

Karidine acts as an inhibitor of the Na^+/ K^+-ATPase (Sodium-Potassium Pump), an enzyme that mediates the active transport of Na^+ and K^+ across the cell membrane. This primary molecular action directly affects cellular ion homeostasis by blocking the export of Na^+ and the import of K^+.

This inhibition initiates a cascade where the resulting increase in intracellular Na^+ reduces the efficiency of the Na^+/ Ca^2+ Exchanger (NCX). The slowed Ca^2+ efflux leads to an accumulation of intracellular calcium ( Ca^2+) within myocardial cells, engaging Ca^2+-dependent signaling pathways. The final physiological consequence is the positive inotropic effect, which is an increase in the force of contraction driven by enhanced Ca^2+ binding to myofilaments. The altered ion gradients also influence the electrical properties of the heart, resulting in a change in cardiac electrical conduction (negative dromotropic effect).

Dosage and Administration Information

How Karidine is Used: Administration Guidelines

Karidine, containing Phenazopyridine HCl, is administered according to instructions that define its usage pattern as a temporary, symptomatic aid. This section details the standardized administration parameters.


Standard Usage Parameters

Feature Administration Guideline
Route of Administration The medicine is taken orally (by mouth), typically as a tablet.
Standard Adult Dose The standard adult regimen calls for 200 mg per dose. This dose is achieved by taking either one 200 mg tablet or two 100 mg tablets.
Dosing Frequency Administration is scheduled three times a day (TID) to maintain consistent support during symptomatic periods.

Contextual Use and Duration Constraints

Karidine must be taken with or immediately following food or a snack to mitigate the potential for stomach upset, as specified in prescribing information. The duration of use is specifically constrained: treatment should not exceed 2 days when the drug is used concomitantly with an antibacterial agent for a urinary tract infection.

Population Considerations: Guidance advises caution for use in older adult patients due to the higher potential for age-related decline in renal function. The medicine is contraindicated in patients with a known diagnosis of renal insufficiency.

Procedural Indicator: An important administration restriction is that the medicine must be discontinued immediately if a yellowish tinge to the skin or eyes (sclera) is observed. This sign indicates that the body is retaining the drug due to excretion issues, which automatically halts the appropriate use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Karidine

Evidence Supporting Symptomatic Relief in Urinary Tract Irritation

Research was studied for conditions associated with acute or disruptive episodes, particularly when symptoms become more noticeable. Studies were short-term, randomized, placebo-controlled trials, often used in research exploring symptom changes alongside standard care. These studies monitored patient-reported outcomes describing perceived discomfort, such as pain, burning sensation (dysuria), urgency, and frequency. Findings describe patterns observed in the studies, suggesting patterns observed in the evolution of patient-reported discomfort in the initial 24 to 72 hours.

Research Evidence for Use Following Procedures

Research also examined the use of Karidine in procedural settings, such as following ureteral stent placement or various endoscopic and surgical interventions. Studies explored discomfort that can arise after procedures, monitoring outcomes related to physical discomfort. Some randomized trials reported measurements that described patterns observed in immediate postoperative pain scores. However, when research examined specific functional outcomes, such as voiding success rates, findings were mixed.

Understanding Long-Term Studies and Extended Follow-up

The studies that were conducted evaluated Karidine only as an agent for short-term, supportive symptom evaluation. Accordingly, long-term effects are not fully established, and follow-up durations were limited across the existing body of research. Studies have not typically been designed to evaluate its full impact when used for durations longer than studied.

Evaluation of Evidence in Specific Patient Populations

Dedicated research examining the use of Karidine in certain populations remains insufficient. Data for certain groups, such as children, remain insufficient, meaning there are limited studies evaluating its use in pediatric settings. Similarly, evidence is limited regarding specific subpopulations, such as older adults with complex comorbid conditions.

Evidence Gaps and Areas of Research Uncertainty

The research contributes to the broader evidence landscape but also reveals several areas where more information is needed. Certainty remains low regarding the consistency of results across all possible scenarios, as evidence quality varies across studies. Comparative evidence is lacking to fully understand how observed short-term changes relate to or differ from other methods of symptomatic relief.

Key Studies & References Label: PHENAZOPYRIDINE HCL tablet - DailyMed - NIH (Official Labeling and Indication Statement)

Frequently Asked Questions (FAQ)

Common questions about Karidine (FAQ)


Q: How quickly does Karidine start working?

Official information indicates that Karidine is intended to provide quick symptomatic relief. It is used to provide symptomatic relief during the period before antibacterial treatment takes full effect.


Q: Is it normal to feel sleepy when taking Karidine?

Official safety information lists certain neurological effects, such as headache and vertigo (a sensation of dizziness or spinning). While dizziness is noted, the drug is not typically listed with drowsiness or excessive sleepiness as a common side effect in regulatory documents.


Q: Can I take Karidine if I am pregnant?

Karidine is classified as Pregnancy Category B. Regulatory documentation states that the medicine should be used during pregnancy only if it is clearly needed.


Q: Can I use Karidine while breastfeeding?

Official labeling states that it is not known whether the medicine or its byproducts are excreted in human milk. Due to this uncertainty, regulatory documents outline that a decision regarding discontinuing nursing or discontinuing the drug is required, based on the necessity of the drug to the mother.


Q: Is there a maximum time someone can take Karidine?

Regulatory documents specify a clear limit for its primary use: treatment should not exceed 2 days when the medicine is used at the same time as an antibacterial agent for a urinary tract infection. This time limit is specified in regulatory documents and applies when Karidine is used along with an antibacterial agent.


Q: Can Karidine be taken with blood pressure medication?

Official labeling notes that the interaction of Karidine with other drugs has not been studied in a systematic manner. However, the available information suggests that no significant interactions between Karidine and other systemic medications have been specifically reported.


Q: What should I know about taking Karidine if I have diabetes?

Official labeling specifies that Karidine, due to its properties as an azo dye, can interfere with the results of certain color-based laboratory tests. This includes urinalysis for substances like glucose (sugar) and ketones, which are relevant to diabetes monitoring.


Q: Is the research evidence for Karidine considered strong?

Studies are limited to short-term, supportive symptom evaluation. Regulatory summaries indicate that the certainty remains low regarding the consistency of results across all scenarios, and comparative evidence against other methods is generally lacking.


Q: Is Karidine the same as or similar to [Name of similar medicine]?

Karidine's function is highly specific; it is classified as a Urinary Tract Analgesic because it provides localized pain relief directly on the urinary system's lining. Its active ingredient is a synthetic azo dye derivative, which defines its unique mechanism and effect.


Q: What kind of drug class does Karidine belong to?

Karidine is officially classified by regulatory authorities as a Urinary Tract Analgesic. It is also considered a member of the broader class of miscellaneous genitourinary tract agents, as its action is specific to the urinary system.


Q: Can Karidine cause stomach upset?

Yes, official safety information lists occasional gastrointestinal disturbance as a possible adverse reaction. This is why the product is advised to be taken with or immediately following food or a snack, which may help reduce this potential effect.


Q: Why does the official information say Karidine can cause a rare side effect called [Specific rare condition]?

Serious adverse reactions such as Methemoglobinemia are listed because they have been reported, primarily in specific, high-risk conditions. These are often associated with use at overdosage levels or in individuals with pre-existing impaired renal function that leads to drug accumulation.


Q: Where can I find reliable research on Karidine?

Research summaries and the full official drug information are available from governmental and intergovernmental bodies. You can typically find this information directly from agencies such as the NIH (DailyMed/MedlinePlus) in the United States or the EMA in Europe.


Q: What makes Karidine different from other drugs for the same condition?

Karidine's function is strictly as a Urinary Tract Analgesic that works directly on the urinary tract mucosa to provide local, symptomatic relief of pain, burning, and irritation. It does not possess any properties to treat the underlying condition itself.


Q: How do doctors monitor the effects of Karidine?

The effectiveness of Karidine is generally evaluated by reviewing the patient’s subjective report of the original urinary tract symptoms (pain, burning, urgency). The presence of a yellowish tinge to the skin or eyes is an official sign that drug accumulation may be occurring, which serves as an official indicator that the medication should be discontinued.


Q: When did Karidine first become available?

The active ingredient in Karidine, Phenazopyridine, was first approved by the US Food and Drug Administration (FDA) in September 1987, marking its initial availability.


Q: Can I stop taking Karidine suddenly?

Official documents state that Karidine is used for symptomatic relief only and should be discontinued once the initial symptoms of discomfort are controlled. This typically occurs after 2 days when the drug is used alongside an antibacterial agent.

How should Karidine be stored and disposed of?

How to Store and Dispose of Karidine?

The storage and disposal of Karidine (Phenazopyridine Hydrochloride) must adhere strictly to regulatory labeling to maintain stability and ensure safety.

Storage Conditions

Item Regulatory Requirement
Temperature Store at controlled room temperature, between 20°C and 25°C.
Environmental Protect from moisture and keep the container tightly closed.
Safety Keep the medication out of the reach of children.

Disposal Instructions

Unused or expired Karidine must be disposed of according to local regulations for pharmaceutical waste. Health authorities recommend utilizing drug take-back programs as the preferred disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Karidine found in:

A-Z Index: